Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis
Year: 2010
Type: editorial
Abstract: The ADA and the EASD recently published a consensus statement for the medical management of hyperglycaemia in patients with type 2 diabetes. The authors advocate initial treatment with metformin monotherapy and lifestyle modification, followed by addition of basal insulin or a sulfonylurea if glycaemic goals are not met (tier 1 recommendations). All other glucose-lowering therapies are relegated to a secondary (tier 2) status and only recommended for selected clinical settings. In our view, this algorithm does not offer physicians and patients the appropriate selection of options to individualise and optimise care with a view to sustained control of blood glucose and reduction both of diabetes complications and cardiovascular risk. This paper critically assesses the basis of the ADA/EASD algorithm and the resulting tiers of treatment options.
Source: Diabetologia
Institutions: Krankenanstalt Rudolfstiftung der Stadt Wien, Heart of England NHS Foundation Trust, University of Birmingham, University College Hospital, University College London, Universitat de València, University of Udine, Centre Hospitalier Universitaire de Nantes, Université de Nantes, Nantes Université, GWT-TUD GmbH (Germany), University of Zurich, University Hospital Zurich, Jagiellonian University, Lahey Hospital and Medical Center, University of Latvia, University of Liège, University of Freiburg, University Medical Center Freiburg, Karolinska Institutet, University of Ioannina, The University of Texas at San Antonio Health Science Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,490
OpenAlex ID: W2098674879
